MGP Database

New search | Record Overview | Ontology/Pathway Information | Domain Information | UniProt Annotations | Related Proteins
MGP003250

UniProt Annotations

Entry Information
Gene Nameubiquitin-conjugating enzyme E2L 3
Protein EntryUB2L3_HUMAN
UniProt IDP68036
SpeciesHuman
Comments
Comment typeDescription
Alternative ProductsEvent=Alternative splicing; Named isoforms=3; Name=1; IsoId=P68036-1; Sequence=Displayed; Name=2; IsoId=P68036-2; Sequence=VSP_045152; Name=3; IsoId=P68036-3; Sequence=VSP_047342; Note=No experimental confirmation available.;
Catalytic ActivityATP + ubiquitin + protein lysine = AMP + diphosphate + protein N-ubiquityllysine. {ECO:0000255|PROSITE- ProRule:PRU00388, ECO:0000255|PROSITE-ProRule:PRU10133}.
CautionPubMed:10760570 reported that UBE2L1, UBE2L2 and UBE2L4 are most likely pseudogenes and the only expressed member of this subfamily seems to be UBE2L3. {ECO:0000305}.
DomainIn contrast to other ubiquitin-conjugating enzymes E2, residues essential for lysine reactivity are absent: Pro and a His residues are present instead of an Asp and an Asp residues in positions 88 and 119,respectively. {ECO:0000269|PubMed:21532592}.
FunctionUbiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine: in contrast, it has activity with the RBR family E3 enzymes, such as PARK2 and ARIH1, that function like function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-linked polyubiquitination. Involved in the selective degradation of short-lived and abnormal proteins. Down- regulated during the S-phase it is involved in progression through the cell cycle. Regulates nuclear hormone receptors transcriptional activity. May play a role in myelopoiesis. {ECO:0000269|PubMed:10888878, ECO:0000269|PubMed:15367689, ECO:0000269|PubMed:17003263, ECO:0000269|PubMed:18946090, ECO:0000269|PubMed:19340006, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21532592}.
InteractionQ9Y4X5:ARIH1; NbExp=5; IntAct=EBI-711173, EBI-2514233; O95376:ARIH2; NbExp=8; IntAct=EBI-711173, EBI-711158; Q99PZ6:ospG (xeno); NbExp=3; IntAct=EBI-711173, EBI-9316527; Q6ZMZ0:RNF19B; NbExp=2; IntAct=EBI-711173, EBI-2466594;
PathwayProtein modification; protein ubiquitination. {ECO:0000255|PROSITE-ProRule:PRU00388}.
PtmUbiquitinated. The alteration of UBE2L3 protein levels during the S-phase of the cell cycle is due to ubiquitin-dependent proteasomal degradation. {ECO:0000269|PubMed:18946090}.
SimilarityBelongs to the ubiquitin-conjugating enzyme family. {ECO:0000255|PROSITE-ProRule:PRU00388}.
Subcellular LocationNucleus. Cytoplasm.
SubunitInteracts with PARK2; involved in ubiquitination and degradation of misfolded proteins. Interacts with UBE3A; used by the papilloma virus HPV-16 E6 protein to ubiquitinate p53/TP53. Interacts with CCNB1IP1, CBL, ZAP70, RNF19A, RNF19B and RNF144B. Interacts with ARIH1. Interacts with ARIH2 (via RING-type 1). Interacts with NCOA1; they functionally interact to regulate progesterone receptor transcriptional activity. May interact with NR3C1. {ECO:0000269|PubMed:10558980, ECO:0000269|PubMed:10888878, ECO:0000269|PubMed:10966114, ECO:0000269|PubMed:11237715, ECO:0000269|PubMed:11278816, ECO:0000269|PubMed:12612082, ECO:0000269|PubMed:15367689, ECO:0000269|PubMed:16427630, ECO:0000269|PubMed:16709802, ECO:0000269|PubMed:17003263, ECO:0000269|PubMed:19340006, ECO:0000269|PubMed:21532592}.
Tissue SpecificityUbiquitous, with highest expression in testis.
  logo